These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 32014739)

  • 41. Nanoscale Coordination Polymer Based Nanovaccine for Tumor Immunotherapy.
    Zhao H; Xu J; Li Y; Guan X; Han X; Xu Y; Zhou H; Peng R; Wang J; Liu Z
    ACS Nano; 2019 Nov; 13(11):13127-13135. PubMed ID: 31710460
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Personalized Nanovaccine Coated with Calcinetin-Expressed Cancer Cell Membrane Antigen for Cancer Immunotherapy.
    Xiong X; Zhao J; Pan J; Liu C; Guo X; Zhou S
    Nano Lett; 2021 Oct; 21(19):8418-8425. PubMed ID: 34546061
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polyethyleneimine modification of aluminum hydroxide nanoparticle enhances antigen transportation and cross-presentation of dendritic cells.
    Dong H; Wen ZF; Chen L; Zhou N; Liu H; Dong S; Hu HM; Mou Y
    Int J Nanomedicine; 2018; 13():3353-3365. PubMed ID: 29922056
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy.
    Zhao P; Xu Y; Ji W; Li L; Qiu L; Zhou S; Qian Z; Zhang H
    Int J Nanomedicine; 2022; 17():73-89. PubMed ID: 35027827
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Harnessing Dendritic Cells for Poly (D,L-lactide-
    Koerner J; Horvath D; Groettrup M
    Front Immunol; 2019; 10():707. PubMed ID: 31024545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aluminum nanoparticles deliver a dual-epitope peptide for enhanced anti-tumor immunotherapy.
    Bai S; Jiang H; Song Y; Zhu Y; Qin M; He C; Du G; Sun X
    J Control Release; 2022 Apr; 344():134-146. PubMed ID: 35217098
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glycosylation of OVA antigen-loaded PLGA nanoparticles enhances DC-targeting for cancer vaccination.
    Chou PY; Lin SY; Wu YN; Shen CY; Sheu MT; Ho HO
    J Control Release; 2022 Nov; 351():970-988. PubMed ID: 36220488
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor Lysate-Loaded Lipid Hybrid Nanovaccine Collaborated with an Immune Checkpoint Antagonist for Combination Immunotherapy.
    Hu X; Wu T; Qin X; Qi Y; Qiao Q; Yang C; Zhang Z
    Adv Healthc Mater; 2019 Jan; 8(1):e1800837. PubMed ID: 30506847
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo.
    Luo Z; Wang C; Yi H; Li P; Pan H; Liu L; Cai L; Ma Y
    Biomaterials; 2015 Jan; 38():50-60. PubMed ID: 25457983
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells.
    Heo MB; Cho MY; Lim YT
    Acta Biomater; 2014 May; 10(5):2169-76. PubMed ID: 24394635
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glucosylated Nanovaccines for Dendritic Cell-Targeted Antigen Delivery and Amplified Cancer Immunotherapy.
    Liu J; Cui Y; Cabral H; Tong A; Yue Q; Zhao L; Sun X; Mi P
    ACS Nano; 2024 Sep; 18(37):25826-25840. PubMed ID: 39196858
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biomimetic virus-like mesoporous silica nanoparticles improved cellular internalization for co-delivery of antigen and agonist to enhance Tumor immunotherapy.
    Gao Y; Zhang Y; Xia H; Ren Y; Zhang H; Huang S; Li M; Wang Y; Li H; Liu H
    Drug Deliv; 2023 Dec; 30(1):2183814. PubMed ID: 36843529
    [TBL] [Abstract][Full Text] [Related]  

  • 53. pH-Responsive Biomimetic Polymeric Micelles as Lymph Node-Targeting Vaccines for Enhanced Antitumor Immune Responses.
    Yang X; Yu T; Zeng Y; Lian K; Zhou X; Ke J; Li Y; Yuan H; Hu F
    Biomacromolecules; 2020 Jul; 21(7):2818-2828. PubMed ID: 32496052
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses.
    Liu X; Feng Z; Wang C; Su Q; Song H; Zhang C; Huang P; Liang XJ; Dong A; Kong D; Wang W
    Biomaterials; 2020 Feb; 230():119649. PubMed ID: 31791843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy.
    Suzuki R; Oda Y; Utoguchi N; Namai E; Taira Y; Okada N; Kadowaki N; Kodama T; Tachibana K; Maruyama K
    J Control Release; 2009 Feb; 133(3):198-205. PubMed ID: 19000727
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Engineered Nanovaccine Targeting Clec9a
    Gou S; Liu W; Wang S; Chen G; Chen Z; Qiu L; Zhou X; Wu Y; Qi Y; Gao Y
    Nano Lett; 2021 Dec; 21(23):9939-9950. PubMed ID: 34779631
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nanovaccine-Based Strategies to Overcome Challenges in the Whole Vaccination Cascade for Tumor Immunotherapy.
    Qin L; Zhang H; Zhou Y; Umeshappa CS; Gao H
    Small; 2021 Jul; 17(28):e2006000. PubMed ID: 33768693
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines.
    Li N; Zhang Y; Han M; Liu T; Wu J; Xiong Y; Fan Y; Ye F; Jin B; Zhang Y; Sun G; Sun X; Dong Z
    Sci China Life Sci; 2024 Apr; 67(4):680-697. PubMed ID: 38206438
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
    Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
    Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metal-Phenolic Network-Encapsulated Nanovaccine with pH and Reduction Dual Responsiveness for Enhanced Cancer Immunotherapy.
    Zhou X; Su Q; Zhao H; Cao X; Yang Y; Xue W
    Mol Pharm; 2020 Dec; 17(12):4603-4615. PubMed ID: 33175556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.